Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Silence Therapeutics Plc LSE:SLN London Ordinary Share GB00B9GTXM62 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.00p -1.43% 69.00p 69.50p 70.50p 69.00p 69.00p 69.00p 41,901 13:07:59
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -20.5 -26.2 - 50.00

Silence Therapeutics Share Discussion Threads

Showing 50376 to 50399 of 50600 messages
Chat Pages: 2024  2023  2022  2021  2020  2019  2018  2017  2016  2015  2014  2013  Older
DateSubjectAuthorDiscuss
06/9/2018
14:56
Perhaps some buying in anticipation of a positive update on the litigation with the half-year results on Tuesday? Conference call for analysts scheduled for that day.
1gw
06/9/2018
11:28
Some nice crosses appearing on the charts. Bodes well
volsung
30/8/2018
19:54
Spend 20% of their Cash on SLN and i'd be happy enough.
frndlyfire
30/8/2018
16:11
Settling the patent dispute.
waterloo01
30/8/2018
16:06
Ticking for?
viku111
30/8/2018
12:35
The clock is now ticking..... htTp://investors.alnylam.com/news-releases/news-release-details/alnylam-receives-approval-onpattrotm-patisiran-europe Edit: As of the most recent Alnylam accounts they had $1.5bn in cash.
waterloo01
23/8/2018
19:00
Thanks for the info both.
1gw
23/8/2018
18:00
Dirk's been around, and often a lone RNai voice for many years. Doesn't always get it right but he knows the companies in this space well.
waterloo01
23/8/2018
17:31
This guy calls himself the RNAiAnalsyt - and his speculation is below. Dirk Haussecker ‏ @RNAiAnalyst Aug 20 More Dirk Haussecker Retweeted Volker Schulz $SLN stock up 17%...settlement in $ALNY to be announced on official EU approval?
frndlyfire
23/8/2018
15:51
All to do with ALNY and getting the 1st RNai approval and that tSLN have a claim on that and other patents. It would a sensible move from them to just buy SLN or they will be in patent disputes for years.
waterloo01
23/8/2018
15:47
Should dispense with their senior executives more often. Works every time!
callumross
23/8/2018
15:47
Doesn't usually move like this. Summink's up
djnzloop
23/8/2018
15:37
Back to 150 bid, just like that. Very nice, but what's it all about? Just low volume summer trading or something else?
1gw
20/8/2018
16:15
We got a lot of mentions in the news this weekend on the back of the ALNY approval. Also had Peel Hunt reiterate its Buy rating a few weeks ago - has anyone read that btw?
frndlyfire
20/8/2018
12:31
Perhaps everyone should leave then!
djnzloop
20/8/2018
09:57
And once again, the shareprice reaction to a sudden departure at the top is to spike...
1gw
20/8/2018
09:53
Another sudden departure. Was she hoping to get the CEO job or was it just job done once the new CEO was in place?
1gw
16/8/2018
19:32
I'm also hoping for that outcome, but clearly there's a risk that the Silence strategy misfires. If Alny believe SLN don't have a reasonable case then they may just play hardball and hope that their greater resources will eventually be enough to force SLN to try to settle for a minimal amount in order to stop the drain on their own resources.
1gw
16/8/2018
18:35
That's also my thinking.
waterloo01
16/8/2018
17:51
Why doesn't ALNY buy SLN? For a company that size it would surely be drop in the ocean, and make all this lawsuit noise go away. What am i missing?
frndlyfire
16/8/2018
08:55
Maybe make my next purchase at 90p?
volsung
10/8/2018
20:57
hTtps://www.statnews.com/2018/08/10/fda-alnylam-rnai-patisiran-onpattro/ Time to pay up!
waterloo01
08/8/2018
17:06
hey @buywell what was the Daily Mail spin? SLN already commented on this in an RNS on the 7th. SLN are now litigating for a potentially increasingly successful use of their IP - doesn't seem like a negative to me as they were already litigating.
djnzloop
08/8/2018
14:19
piece in the Daily Mail today stockwatch didn't read too good, about this On 3 August 2018, Alnylam Pharmaceuticals Inc. ("Alnylam") announced that the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) had granted its RNAi medicine, patisiran, a positive scientific opinion through the Early Access to Medicines Scheme. Further to this decision, Alnylam can provide eligible adults in the UK with access to patisiran before the drug is granted EU marketing authorisation by the European Commission. Grant of the EU marketing authorisation for patisiran is imminent.
buywell3
Chat Pages: 2024  2023  2022  2021  2020  2019  2018  2017  2016  2015  2014  2013  Older
Your Recent History
LSE
SLN
Silence Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190626 12:36:04